Drug marketability

The Prescription Drug Marketing Act of 1988 amended the FD C Act to estabUsh newer safeguards for the national distribution of prescription dmg products. It limits the reimportation of dmg products manufactured in the United States to the product manufacturers only. It also prohibits the selling, trading, and purchasing of sample dmg products and places restrictions upon their distribution. 

Table 3. Quinoline-Derived Drugs Marketed in the United States ...

This will help to lead to a situation where generically-designated drugs are expected to account for 40% of the prescription drug market by 1990. 

Evaluation of applications for drug marketing authorisations made either directly to the national authority or indirectly via the centralised procedure to the EMEA... 

Just as with drugs, market vigilance systems are required to ensure that problems with devices are identified and addressed in a timely manner. Although they share... 

Originally, PCP entered the illegal drug market in the form of tablets, which had a slow onset of action. Since the 1970s, PCP has been produced in... 

Property Marketed oraf Marketed oraF Launched drugs Marketed drugs ... 

The U.S. prescription drug market in 1999 increased by 19%, totaling 2.7 billion, representing 2.7 billion prescriptions, a 9% increase over the prior year [8]. 

Second, we analyse the position of the leading products in the different therapeutic and generic drug markets. Our aim is to evaluate the extent to which the leaders achieve dominant positions in each market. Positions of dominance are shown in terms of the market share of the most frequendy prescribed active ingredient, product or presentation in its therapeutic group of active ingredients, products or presentations, called v, in which g = 1,2,..., G are mutually exclusive groups. 

In 1993, a significant advance in simplifying the procedures relating to drug marketing authorization applications in the EU was made. At that time, the legal basis of a new drug approval system... 

Prescription Drug Marketing Act, 18 686 Prescription drugs, 21 575 Prescription Drug User Fee Act, 78 686 Presedimentation reservoir, in water treatment, 26 103... 

Relatively few drugs marketed in the United States (approximately 20%) have pediatric dosing information available. Clinical trials had rarely been done specifically on pediatric patients. Traditionally, dosing regimens for children have been derived empirically by extrapolating on the basis of body weight or surface area. This approach assumes that the pediatric patient is a young adult, which simply may... 

To show a more complete picture on failed drugs, drugs that have been removed from the market and have been reintroduced later on with some restrictions as well as drugs that have been suspended from most drug markets but still remain on the market in only a few countries are listed in Table 1.2. As these drugs remain available on the Western market, they are not included in our statistics. 

The continuous advancements made in computer technology programs to expedite information increase the access of information to its perspective audience. This enables the information to become more accessible and attainable. The submission coordinators of the FDA work with drug marketers on technical issues relating to labeling submissions. The SPL and Electronic Submission Guideline documents are part of these advancements. 

A brand name drug is a drug marketed under a proprietary, trademark-protected name. 

Services (HHS) and spells out research, enforcement, and education requirements. The Prescription Drug Marketing Act prevents the resale of diverted drugs, requires drug wholesalers be licensed, restricts reimportation, and bans the sale, trade, or purchase of drug samples or counterfeit drug coupons. 

The current counterfeit drugs market is estimated to be about US 40 billion and is expected to increase to almost US 80 billion by 2010. Most of the counterfeit drugs are found in developing countries, where the enforcement of the regulatory authorities is weak or ineffective. In general, the distribution of counterfeit drugs as a proportion of the total market is as follows ... 

One of the first compounds reported to inhibit 5-LO was the NSAID benox-aprofen (167) (reviewed in [405]). This drug (marketed by Lilly as Oraflex ) was effective in rheumatoid arthritis, but was withdrawn because of phototoxicity, liver toxicity and reports of drug-related deaths [406]. The typical NSAID anti-inflammatory profile of this compound was remarkable for its very weak seminal vesicle CO activity [407]. Additional in vivo activities were found for benoxaprofen which were not shared by other NSAIDs, particularly inhibition of leukocyte influx in the carrageenan sponge, carrageenan pleurisy, and rat Arthus pleurisy models monocytes were affected more than neutrophils [408-411]. More recently, benoxaprofen was reported to inhibit the adhesion of monocytes to endothelium [412]. 

---